Improving the effectiveness of a probiotic bacteria for treating inflammatory bowel disease
Official title: Enhancing E. coli Nissle colonization with CRISPR-Cas immunity
Funded at Ancilia, INC. · NIH-11007627 · Data updated 2026-11-12
This study is looking at ways to make a special probiotic, E. coli Nissle, work better for people with inflammatory bowel disease (IBD) by using a new technology to help it survive in the gut, so patients can have a more effective treatment option.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ancilia, INC. NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 19, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $274,401 |
| NIH project number | 1R41DK141344-01 |
| Project ID | NIH-11007627 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with inflammatory bowel disease, particularly those who have not responded well to existing treatments.
✕Less likely to help
Patients with non-inflammatory bowel conditions or those who do not have a diagnosis of inflammatory bowel disease may not benefit from this research.
What this research studies
This research focuses on enhancing the colonization of a specific probiotic strain, E. coli Nissle, which is used to treat inflammatory bowel disease (IBD). The approach involves using CRISPR-Cas technology to provide immunity against viruses that can hinder the bacteria's effectiveness in the gut. By understanding and addressing the factors that limit the bacteria's ability to thrive, the research aims to improve patient outcomes. Patients may benefit from a more effective treatment option for IBD that utilizes this enhanced probiotic.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients suffering from inflammatory bowel disease.
How similar studies have gone: Previous research has shown promise in using CRISPR technology to enhance bacterial therapies, indicating potential success for this novel approach.
Where this research is happening
-
Ancilia, INC.
New York, United States Active
Researchers
- Principal investigator: Foley, Matthew Harrison — Ancilia, INC.
- Study coordinator: Foley, Matthew Harrison
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.